sought to examine the efficacy of neoadjuvant immune-immune therapy through the NeoSTAR, which evaluated anti-PD-1 plus anti-CTLA-4 in the treatment of early-stage NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.